Sexual arousal disorders
Conditions
Interventions
Trade Name: Cycloserine
Product Name: Cycloserine
Product Code: N/a
Pharmaceutical Form: Capsule
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Sponsors
LUMC, VRSP
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: For this study we will include 68 healthy sexually functional women between 18-45 years. Participants will be included if they have had no sexual complaints for at least one year, and are sexually active. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 68 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: - Age 45 years - Homosexual orientation - Pregnancy or lactation - Colour blindness - A diagnosis of affective, psychotic or substance related disorder according to DSM 5. - Current or recurrent use (less than 4 weeks before participation) of medication that may affect sexual response. To determine possible sexual side-effects the 'Farmacotherapeutisch kompas' 2015 will be used. - Current or previous disorders of the genitals or treatments for such disorders that may influence the sexual response or the measurement of the response. - Other medical disorders that may influence the sexual response or the measurement of the response. - Current or recurrent use (less than 4 weeks before participation) of medication that may affect or interact with the effects of DCS. To determine possible contra-indications, instructions for use as supplied by 'King Pharmaceuticals' will be used. - Current or previous disorders (like severe anxiety or psychosis, liver disease or severe renal insufficiency, epilepsy) that increase the possibility of side effects of DCS and for which usage of DCS is contraindicated. - Alcohol or drug use on the night and day before participation, as well as alcohol and drug use between test moments (day 1 and day 2).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The aim of the study is: to investigate the effect of DCS on the physiological and subjective correlates reflecting conditioned sexual response, and sexual memory formation. Hypothesis: We hypothesize that administration of DCS after a classical conditioning procedure will enhance sexual memory formation of conditioned sexual responses. Compared to the placebo-condition, for the DCS condition an increase in sexual conditioned responses elicited by reward-conditioned cues will be seen on a test phase 24hrs later. The DCS condition will show stronger conditioned genital and subjective responding, also outside the original acquisition context, compared to the placebo condition. ;Secondary Objective: n.a.;Primary end point(s): 1) measures of vaginal pulse amplitude (VPA) assessed by a vaginal photoplethysmograph; 2) Subjective ratings of US expectancy, affective valence and sexual arousal; 3) implicit attitude;Timepoint(s) of evaluation of this end point: March 31th 2016 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): May 2016 ;Timepoint(s) of evaluation of this end point: May 2016 | — |
Countries
Netherlands
Contacts
Public ContactDr. Philomeen Weijenborg
LUMC, VRSP
Outcome results
None listed